Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sacubitril/valsartan - Novartis

Drug Profile

Sacubitril/valsartan - Novartis

Alternative Names: AHU-377/valsartan; dapagliflozin - Novartis; Enrest; Enresuto; Entresto; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitril

Latest Information Update: 08 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Rovi
  • Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Cardiovascular therapies; Erectile dysfunction therapies; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles; Urologics
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Heart failure; Hypertension
  • Phase III Erectile dysfunction; Kidney disorders
  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 01 Feb 2024 Novartis plans a phase III trial for Hypertension (Treatment naïve, Monotherapy, Combination therapy) (PO, Tablet) (NCT06236061)
  • 04 Dec 2023 Phase-III clinical trials in Heart failure (In children, In adolescents) in Japan (PO) (NCT06149104)
  • 28 Nov 2023 Novartis Pharmaceuticals plans a phase III trial for Heart failure (In adolescents, In children) in December 2023 (PO, capsule) (NCT06149104 )
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top